A Phase 3 interventional study of H5N1 vaccine (Arepanrix, GSK) and Placebo in Influenza (Pandemic), Avian Influenza and Vaccination, sponsored by University Health Network, Toronto. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies in Influenza, Human with a site in Canada — 7 open to participants now, 12 under way, 4 of them phase 3. Influenza, Human · Canada.
Among the 157 studies in Influenza, Human with a site in Canada, this one is the 93rd largest by planned enrollment of the 131 interventional ones that give a count, is one of 2 that started in 2025, is one of 42 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 153rd registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →7 of the 157 studies in Influenza, Human with a site in Canada are open now. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Healthy volunteers
Dalhousie University · Sites in Canada
Ages 18–45 · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 42 · Phase 4 24
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 300 across the 131 interventional studies, 241 across the 26 observational. Of the 131 that completed or were terminated, 62 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 157 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies in Influenza, Human with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT07240558Phase 3University Health Network, TorontoPandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) | 2027-04-30 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07739719McMaster UniversitySAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial) | 2027-02-15 |
| NCT07305207Dalhousie UniversityEstablishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness | 2027-06-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 157 studies in Influenza, Human with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the next influenza pandemic may be soon approaching. Transplant patients will likely be uniquely predisposed to serious infection with high morbidity and mortality. There are a number of important reasons that evaluation of prevention strategies are critical in this highly vulnerable population. Currently, there is no data on the immunogenicity of H5Nx vaccines in this highly vulnerable population. The investigators plan to study the safety and immunogenicity of a two-dose regimen of the pandemic influenza H5N1 vaccine in organ transplant patients.
This randomized, placebo-controlled, double-blind, single-centre trial will evaluate the immunogenicity and safety of a two-dose regimen of the AS03-adjuvanted inactivated H5N1 vaccine (AREPANRIX™ H5N1, GSK) in adult organ transplant recipients. A total of 120 stable outpatient organ transplant recipients at the University Health Network (Toronto, Canada) will be enrolled and randomized 1:1 to receive two doses of H5N1 vaccine or placebo (0.9% saline) administered intramuscularly 3 weeks apart.
Blood samples collected at baseline (V0), 3 weeks (V1), and 6 weeks (V2) will be analyzed for serologic responses using hemagglutination inhibition (HAI) assays against vaccine and circulating H5N1 strains. In a subset of 60 participants (30 per arm), peripheral blood mononuclear cells will be obtained at each time point to assess cell-mediated immunity, including H5-specific CD4+ and CD8+ T-cell cytokine responses and B-cell immunity.
Participants will be monitored for local and systemic adverse events for 7 days following each dose and followed for 6 months for any adverse events, including rejection, influenza-like illness, and laboratory-confirmed influenza. Long-term immunogenicity will also be assessed at 6 months in vaccine recipients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will receive 2 doses of approved H5N1 vaccine, 3 weeks apart
Biological: H5N1 vaccine (Arepanrix, GSK)
This arm will receive 2 doses of normal saline (placebo), 3 weeks apart
Biological: Placebo
2 doses of H5N1 vaccine, 3 weeks apart, given IM (deltoid)
2 doses of 0.5mls normal saline, 3 weeks apart, given IM (deltoid)
Seroprotection and seroconversion 6 weeks after dose 1
Participants with seroprotection (HAI titers greater than or equal to 1:40) after dose 2 AND seroconversion, defined as greater than or equal to 4-fold increase in HAI antibody titers from baseline to after dose 2 to the vaccine-matched H5 avian influenza strain.
Time frame: 6 weeks after dose 1 and 3 weeks after dose 2
Seroprotection and seroconversion after dose 1 and comparison with after dose 2
Time frame: 6 weeks after dose 1
T and B cell immunity after dose 1 and dose of vaccine
Time frame: 3 and 6 weeks post dose 1
Durability of immunity at 6 months post dose 1
Time frame: 6 months post dose 1
Local and systemic adverse events to vaccination
Time frame: Until 6 months post dose 2
Other safety factors
Transplant rejection, influenza like illness, confirmed influenza episodes
Time frame: Until 6 months post dose 2
Seroprotection and seroconversion after dose 1 and 2 to H5, H1, H3
Time frame: 6 weeks and 3 weeks post dose 1
Plan to share: No — Deidentified aggregated data will only be shared with appropriate request and ethical approval.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.
Of 35 non-industry phase 3 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 17 months is close to that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jun 2026 → Apr 2027 and completion Dec 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →